2 weeks Ago By ABMN Staff
Envestnet Asset Management Inc. increased its position in shares of Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY – Free Report ) by 110.
5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 66,014 shares of the biopharmaceutical company’s stock after purchasing an additional 34,647 shares during the period. Envestnet Asset Management Inc.
owned about 0.05% of Alnylam Pharmaceuticals worth $15,534,000 at the end of the most recent reporting period. A number of other large investors have also modified their holdings of ALNY.
Aviva PLC increased its holdings in Alnylam Pharmaceuticals by 215.2% in the 4th quarter. Aviva PLC now owns 77,244 shares of the biopharmaceutical company’s stock valued at $18,176,000 after buying an additional 52,738 shares during the period.
Resona Asset Management Co. Ltd. acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $8,637,000.
Prudential PLC increased its stake in Alnylam Pharmaceuticals by 41.9% in the fourth quarter. Prudential PLC now owns 4,280 shares of the biopharmaceutical company’s stock valued at $1,007,000 after acquiring an additional 1,264 shares during the period.
Motley Fool Asset Management LLC raised its position in Alnylam Pharmaceuticals by 7.9% in the fourth quarter. Motley Fool Asset Management LLC now owns 1,899 shares of the biopharmaceutical company’s stock worth $447,000 after purchasing an additional 139 shares in the last quarter.
Finally, Westpac Banking Corp raised its position in Alnylam Pharmaceuticals by 83.9% in the fourth quarter. Westpac Banking Corp now owns 10,560 shares of the biopharmaceutical company’s stock worth $2,485,000 after purchasing an additional 4,819 shares in the last quarter.
92.97% of the stock is currently owned by institutional investors and hedge funds. Analyst Ratings Changes Several equities research analysts have recently weighed in on ALNY shares.
Scotiabank upped their price objective on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a “sector outperform” rating in a research note on Monday, March 31st.
Redburn Atlantic assumed coverage on Alnylam Pharmaceuticals in a research report on Monday, March 31st. They issued a “buy” rating and a $353.00 price target on the stock.
Morgan Stanley cut their price objective on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating for the company in a report on Friday, April 11th.
Chardan Capital reaffirmed a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Finally, Bank of America lifted their price target on shares of Alnylam Pharmaceuticals from $302.
00 to $325.00 and gave the company a “buy” rating in a report on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have issued a buy rating to the company.
Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $315.58.
Insider Buying and Selling In other news, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.
21. Following the transaction, the chief executive officer now owns 81,526 shares in the company, valued at $20,802,989.42.
The trade was a 1.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink .
Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.
23. Following the sale, the executive vice president now directly owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41.
The trade was a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
Insiders have sold 71,234 shares of company stock valued at $19,958,097 in the last 90 days. 1.50% of the stock is owned by insiders.
Alnylam Pharmaceuticals Stock Performance Shares of Alnylam Pharmaceuticals stock opened at $230.93 on Wednesday. The firm has a fifty day moving average of $251.
53 and a two-hundred day moving average of $257.83. The company has a debt-to-equity ratio of 15.
27, a quick ratio of 2.71 and a current ratio of 2.78.
The stock has a market capitalization of $30.04 billion, a price-to-earnings ratio of -106.42 and a beta of 0.
30. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.
98 and a 52 week high of $304.39. Alnylam Pharmaceuticals ( NASDAQ:ALNY – Get Free Report ) last released its quarterly earnings data on Thursday, February 13th.
The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.
03). As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.
7 EPS for the current year. About Alnylam Pharmaceuticals ( Free Report ) Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Featured Articles Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY – Free Report ).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
